Molecular genetic alterations as potential prognostic indicators in colorectal carcinoma and molecular genetics of colorectal carcinoma
S. Hamilton,S. Kern
DOI: https://doi.org/10.1002/1097-0142(19930801)72:3<957::AID-CNCR2820720349>3.0.CO;2-1
IF: 6.9209
1993-08-01
Cancer
Abstract:Clinical application of the molecular genetics of human cancers is an important goal, particularly in light of rapidly advancing basic knowledge. However, clinical utility must be demonstrated in convincing fashion before molecular genetics, or any other methodology, can be moved from the research arena into patient management. As an example, allelic deletions as prognostic markers in colorectal cancer have generated considerable interest but have not yet reached the point of clinical application. In two recent reviews in Cancer,',2 one of us (S.R.H.) pointed out that allelic deletion of the p53 gene region on the short arm of chromosome 17 (17p), deletion of the dcc gene region on the long arm of chromosome 18 (18q), and high fractional allelic loss (fraction of evaluable nonacrocentric autosomal arms with deletion) in primary colorectal cancers have been associated with disseminated disease and may eventually be useful markers for poorer prognosis in patients without initial evidence of disseminated disease. The first study of allelic deletions in relation to prognosis included a subset of patients with Dukes B or C (Stage I1 and 111) dise a ~ e . ~ , ~ The 18 patients with allelic deletion of 17p had poorer survival (P = 0.045) than the 8 patients without 17p d e l e t i ~ n . ~ In univariate analysis, the 16 patients with 18q deletion and the 10 patients with greater than median fractional allelic loss had poorer survival than the corresponding comparison groups, but the differences were not statistically significant, and our study lacked the statistical power to resolve the contribution of these latter two molecular genetic alteration^.^,^ A recent report of a larger study of 109 patients with AstlerColler Stage A, B1, B2, or C1 colorectal cancer showed that 17p deletion, but not 18q deletion, was associated with statistically significantly poorer survival in multivariate ana ly~ i s .~ By contrast, another study of 60 patients with Astler-Coller Stage B or C colorectal cancer showed a significant association between 18q allelic deletion and tumor recurrence, but not between 17p deletion and o ~ t c o m e . ~ , ~ Thus, the individual contribution of 17p deletion and 18q deletion is not yet established and may be difficult to determine due to the high prevalence of each alteration. Allelic deletion analysis of colorectal cancers is now marketed by at least one commercial laboratory, but clinical decision making regarding patient prognosis and therapeutic approaches should await additional research studies, which are in progress in various institutions and cooperative groups.